

SUMMARY TABLE

An initial interpretation of the results obtained from the patients genetic profile is displayed in a table below. For each drug examined, the result is indicated according to the following code:

- Standard (White box) ▶ No genetic variants relevant to the treatment have been found. Use as directed.
- Yellow box ▶ Need for drug dose monitoring and/or less likelihood of positive response.
- Green box ▶ Increased likelihood of positive response and/or lower risk of adverse drug reactions.
- Red box ▶ Increased risk of adverse drug reactions.

Antidepressants			
Amitriptyline	Yellow	Bupropion	Standard
Clomipramine	Yellow	Desipramine	Yellow
Duloxetine	Standard	Escitalopram	Standard
Fluvoxamine	Yellow	Imipramine	Yellow
Mirtazapine	Green	Nortriptyline	Yellow
Sertraline	Standard	Trimipramine	Yellow
Citalopram	Red		
Doxepine	Yellow		
Fluoxetine	Yellow		
Mianserin	Yellow		
Paroxetine	Green		
Venlafaxine	Yellow		

Antipsychotics			
Aripiprazole	Yellow	Clozapine	Yellow
Olanzapine	Red	Perphenazine	Yellow
Risperidone	Yellow	Thioridazine	Yellow
Zuclopentixol	Yellow		
Haloperidol	Yellow		
Quetiapine	Standard		
Ziprasidone	Green		

Stabilizers and anticonvulsants			
Carbamazepine	Yellow	Clobazam	Standard
Lamotrigine	Standard	Levetiracetam	Standard
Lorazepam	Yellow	Oxcarbazepine	Standard
Phenytoin	Yellow	Pregabalin	Standard
Valproic Acid	Standard	Vigabatrin	Standard
Clonazepam	Standard		
Lithium*	Green		
Phenobarbital	Standard		
Topiramate	Standard		

Others			
Atomoxetine	Yellow	Methadone	Standard
Naloxone	Standard	Naltrexone	Standard
Methylphenidate	Yellow		
Pramipexol	Green		

Supplementary Fig. 1. Neuropharmagen[®] (AB-Biotics, S.A., Barcelona, Spain) pharmacogenetic report (NPR) used in the study.